Taking people in NorwayPhase 2
Tests atorvastatin for preventing episodic migraine in adults
Tests the cholesterol drug atorvastatin in adults with episodic migraine.
Key facts
- Who runs it
- St. Olavs Hospital HF
- Where
- Bergen, Lørenskog, Oslo, Tromsø, and Trondheim, NorwaySee the 5 sites
- Trial code
- Registry title
- Atorvastatin in episodic migraine
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 450 people, planned
- Started
- 13 May 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 14 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with episodic migraine who have 4-14 migraine days per month. It tests atorvastatin against placebo.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Episodic migraine, with or without aura. It started at least one year before joining and before age 50 years. 4-14 migraine days per month.
- Earlier treatment
- No other migraine preventive medicine during the study. No statins ever used. No migraine preventive medicine in the 4 weeks before the start, and no botulinum toxin in the 16 weeks before. Not tried 3 or more preventive drugs in the last 10 years.
Main reasons for not taking part
- Chronic migraine or other headaches on 15 or more days per month
- Pregnancy, planning pregnancy or breastfeeding
- Liver or kidney problems, or other serious health problems
- Allergy to statins or earlier use of statins
- Alcohol or drug dependence, or a significant psychiatric illness
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Aged 18 to 65 years with 4-14 migraine days per month
- Signed informed consent
- Episodic migraine with or without aura according to ICHD-3 criteria, debut of migraine at least one year prior to inclusion, and start of migraine before age 50 years
- No use of other migraine prophylactics during the study
- For women of child-bearing potential there must be no pregnancy or planned pregnancy during the study period, and use of highly effective contraception
Who cannot take part
- Interval headache not distinguishable from migraine or chronic migraine, chronic tension-type headache, medication overuse headache or other headache occurring on ≥ 15 days/month
- Hypersensitivity to statins or previous use of statins
- Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin less than 16 weeks, prior to start of study
- Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years
- Consistently failing to respond to any acute migraine medication and/or requiring detoxification from acute medication (triptans, opioids)
- Clinical information on signs of cholestasis, decreased hepatic or renal function, high degree of comorbidity, frailty associated with reduced life expectancy, high likelihood of hospitalization at the discretion of the investigator,, history of angioneurotic oedema, current use of antiviral treatment against hepatitis C, significant psychiatric illness, alcohol or illicit drug dependence, inability to understand study procedures and to comply with them for the entire length of the study, and/or treatment for hypothyroidism
- Pregnancy, planning to get pregnant, inability to use contraceptives or lactating
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norway
- Helse Bergen HFBergen, NorwayTaking people
- Akershus University HospitalLørenskog, NorwayTaking people
- Oslo University Hospital HFOslo, NorwayTaking people
- Universitetssykehuset Nord-NorgeTromsø, NorwayTaking people
- St. Olavs hospital HFTrondheim, NorwayTaking people
About the trial
What the trial wants to find out
To evaluate whether the favourable preventative effect ofAtorvastin in two different doses seen in three smaller studies, can be confirmed in a larger multicentre randomized, controlled study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in episodic migraine (StatinMigEpisodic)
- Plain-language title
- Tests atorvastatin for preventing episodic migraine in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2022-502176-23-01, who can take part
- Record updated
- 14 April 2026